Phagoburn

Phagoburn is a clinical trial that was conducted in Europe, which aimed to evaluate the efficacy of bacteriophages in treating burn wound infections. The trial was sponsored by the French company Pherecydes Pharma.

Overview

The Phagoburn trial was a multicenter, randomized, controlled clinical trial that was conducted across several hospitals in France, Belgium, and Switzerland. The trial aimed to evaluate the efficacy and safety of a cocktail of bacteriophages in treating burn wound infections caused by Escherichia coli and Pseudomonas aeruginosa. The trial was sponsored by Pherecydes Pharma, a French biotechnology company that specializes in the development of bacteriophage therapies.

Methodology

The trial involved the application of a cocktail of bacteriophages to the burn wounds of patients. The bacteriophages were specifically chosen for their ability to infect and kill Escherichia coli and Pseudomonas aeruginosa, two bacteria that are commonly found in burn wound infections. The efficacy of the bacteriophage treatment was then compared to that of standard antibiotic treatment.

Results

The results of the Phagoburn trial were mixed. While the bacteriophage treatment was found to be safe and well-tolerated by patients, it was not found to be more effective than standard antibiotic treatment in reducing the bacterial load in burn wounds.

Significance

Despite the mixed results, the Phagoburn trial is significant as it was one of the first clinical trials to evaluate the efficacy of bacteriophage therapy in a controlled setting. The trial has contributed to the growing body of evidence supporting the potential of bacteriophages as an alternative to antibiotics in the treatment of bacterial infections.

See Also

• Bacteriophage
• Pherecydes Pharma
• Clinical trial
• Burn
• Infection

Phagoburn Resources
Latest articles Most recent articles Ongoing trials	Wikipedia